1. Cytogenetic toxicity of cycloplatam in human lymphocytes: detection by the micronucleus test and fluorescence in situ hybridization
- Author
-
Paola Roggieri, Emanuela Perrone, Claudia Bolognesi, and Armen Nersesyan
- Subjects
Male ,Cancer Research ,Organoplatinum Compounds ,Biology ,medicine.disease_cause ,Carboplatin ,chemistry.chemical_compound ,Clastogen ,medicine ,Humans ,Pharmacology (medical) ,Lymphocytes ,In Situ Hybridization, Fluorescence ,Micronuclei, Chromosome-Defective ,Pharmacology ,Cisplatin ,Micronucleus Tests ,medicine.diagnostic_test ,Molecular biology ,Oncology ,chemistry ,Micronucleus test ,Toxicity ,Female ,Chromosome breakage ,Genotoxicity ,medicine.drug ,Fluorescence in situ hybridization - Abstract
Cycloplatam has been shown to be effective in the treatment of pleural mesothelioma, myeloma and ovarian carcinoma. Cycloplatam is not nephrotoxic with respect to the platinum-based anti-tumor agents. We have investigated the mechanism underlying the induction of micronuclei (MN) in human lymphocytes by cycloplatam compared to that by its parent drugs cisplatin and carboplatin. The cytokinesis-block micronucleus assay in human lymphocytes was applied in combination with fluorescence in situ hybridization (FISH) with an all-chromosome centromeric probe allowing discrimination between MN due to chromosomal fragments (centromere negative, C - ) and those containing whole chromosomes (centromere positive, C + ). A statistically significant increase of MN frequency (P
- Published
- 2006